Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19

Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19

Blog Article

COVID-19 in immunocompromised patients is difficult to treat.SARS-CoV-2 interaction with the host immune system and the role of therapy still remains only partly understood.There are no data regarding the use of monoclonal antibodies and the combination Electronics - Headphones of two antivirals in fighting viral replication and disease progression.We report the cases of two patients, both Beard Nets treated with rituximab for non-Hodgkin lymphoma and granulomatosis with polyangiitis, respectively, and both hospitalized for COVID-19 with positive SARS-CoV-2 RNAemia, who were successfully treated with a salvage combination therapy with sotrovimab, remdesivir and nirmatrelvir/ritonavir.